AFFILIATIONS
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Pakistan Kidney and Liver Institute and Research Center, Lahore, Punjab, Pakistan
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 Fred Hutch Center For Community Health Promotion, Sunnyside, Washington, United States
7 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
8 UNC Bone Marrow & Stem Cell Transplant Clinic, Chapel Hill, North Carolina, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
11 University of Michigan, Ann Arbor, Michigan, United States
12 King Hussien Cancer Center, Amman, Jordan, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
13 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
14 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
15 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background:
Total body irradiation (TBI)–based conditioning remains an important component of allogeneic hematopoietic cell transplantation (HCT), but its role in the era of HLA-mismatched transplantation with post-transplant cyclophosphamide (PTCy) is uncertain. Historically, TBI has been associated with improved disease control in selected settings; however, its impact on survival and competing outcomes in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) treated with modern PTCy platforms is not well defined.
Methods:
We performed a retrospective analysis of Center for International Blood and Marrow Transplant Research (CIBMTR) data (P-6144 dataset) including adults with AML or MDS who underwent HLA-mismatched allogeneic HCT with PTCy-based GVHD prophylaxis. Patients receiving TBI-based versus non-TBI conditioning were compared. The primary endpoint was overall survival (OS). Secondary endpoints included relapse-free survival (RFS), relapse, and non-relapse mortality (NRM). Multivariable Cox proportional hazards models were used for OS and RFS; Fine–Gray competing-risk regression was used for relapse and NRM. Propensity-score inverse-probability-of-treatment weighting (IPTW) and propensity-score–adjusted competing-risk analyses were performed as sensitivity analyses.
Results:
A total of 4,903 patients were included: 3,221 received TBI-based conditioning and 1,682 received non-TBI conditioning. TBI recipients were older (median age 61 vs 52 years, p<0.001) and more frequently received reduced-intensity conditioning (76% vs 30%, p<0.001), whereas non-TBI recipients more commonly received myeloablative conditioning (70% vs 23%, p<0.001). Disease distribution was 72% AML and 28% MDS. In multivariable analysis, TBI-based conditioning was not associated with OS (HR 0.98, 95% CI 0.90–1.08, p=0.70) or RFS (HR 0.99, 95% CI 0.90–1.08, p=0.80). In competing-risk analyses, TBI was associated with higher relapse (sHR 1.29, 95% CI 1.14–1.45, p<0.001) and lower NRM (sHR 0.77, 95% CI 0.67–0.88, p<0.001). There was no significant interaction between TBI use and conditioning intensity for OS (p=0.66) or RFS (p=0.48). IPTW and propensity-score–adjusted sensitivity analyses yielded consistent findings, with persistent associations between TBI and higher relapse (sHR 1.22, 95% CI 1.08–1.38, p=0.002) and lower NRM (sHR 0.82, 95% CI 0.71–0.96, p=0.011), while OS and RFS remained similar.
Conclusions:
Among AML/MDS patients undergoing HLA-mismatched allogeneic HCT with PTCy, TBI-based conditioning was not associated with differences in OS or RFS compared with non-TBI conditioning. TBI demonstrated a competing-risk trade-off of higher relapse and lower NRM without affecting survival endpoints. These findings persisted in propensity-score sensitivity analyses and suggest that the observed associations largely reflect differences in patient selection and transplant platform rather than a clear survival advantage of either approach. Prospective studies are needed to define the optimal role of TBI in contemporary HLA-mismatched HCT.